Notably, the CD16xCD33 BiKE demonstrated efficacy in both adult and pediatric AML, enhancing NK cell cytotoxicity, degranulation, and cytokine production against CD33+ AML [155]. The gene discussed is CD33; the disease is acute myeloid leukemia.